ZBIO:NSD-ProShares UltraPro Short NASDAQ Biotechnology (USD)

ETF | Trading--Inverse Equity | NASDAQ Global Market

Last Closing

USD 20.92

Change

+0.10 (+0.48)%

Market Cap

USD 7.18M

Volume

0.10M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ Biotechnology Index?. The fund invests in derivatives that the advisor believes, should have similar daily return characteristics as three times the inverse of the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

Inception Date: 22/06/2015

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.54%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Mer Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ 0.95 %

+0.06 (+0.19%)

USD 2.80B
BIS ProShares UltraShort Nasdaq Bi.. 0.95 %

+0.08 (+0.56%)

USD 3.52M

ETFs Containing ZBIO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 108.78% 50% F 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 108.78% 50% F 78% C+
Trailing 5 Years  
Capital Gain 72.46% 50% F 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.46% 50% F 72% C
Average Annual (5 Year Horizon)  
Capital Gain 3.59% 33% F 49% F
Dividend Return 3.59% 33% F 45% F
Total Return 0.00% 33% F N/A F
Risk Return Profile  
Volatility (Standard Deviation) 18.21% 100% F 81% B-
Risk Adjusted Return 19.69% 100% F 54% F
Market Capitalization 7.18M N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.